Neoadjuvant chemotherapy combined with bevacizumab for resectable colorectal liver metastasis with risk factors for recurrence: a multicenter real-world study

Background: Currently, guidelines prohibit the addition of targeted drugs in neoadjuvant chemotherapy (NAC) for initially resectable colorectal liver metastasis (CRLM). Objective: Nevertheless, efficacy data of NAC combined with bevacizumab (Bev) for initially resectable CRLM with risk factors for r...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Yizhen Chen, Yuanyuan Zheng, Jia Wu, Rong Ye, Hangdong Jia, Zhenyuan Zhou, Weijie Chen, Linwei Xu, Yuhua Zhang, Ming Zheng
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	SAGE Publishing 2025-03-01
Serie:	Therapeutic Advances in Medical Oncology
Accesso online:	https://doi.org/10.1177/17588359251328457
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!